Characteristics of the investigated compound, ST32da. The structure of ST32da was determined by UFLC-MS/MS system. 11 Supplementary Fig. 7 Physiological effects of ATF3 inducer, ST32da, on mouse heart, kidney and liver. Analysis of WT mice fed with HFD for 12 weeks with or without i.p. ST32da treatment at a dose of 1 mg kg -1 per day or 2 mg kg -1 per day. a Serum levels of BUN, creatinine, glucose and triglyceride (TG). b Serum levels of GOT and GPT. c Liver weight. d H&E staining of heart and kidney histology. For a, HFD (n = 7), HFD+1 mg kg -1 per day (n = 7), HFD+2 mg kg -1 per day (n = 4). For b, n = 6 per group. For c, HFD (n = 9), HFD+1 mg kg -1 per day (n = 7), HFD+2 mg kg -1 per day (n = 6). For d, n = 3 per group. Scale bar for image d: 100 µm. Data are presented as mean ± SEM and *p < 0.05 compared to HFD group. Supplementary Fig. 8 The effect of ATF3 inducer, ST32da, in HFD-induced obese ATF3 −/− mice. Analysis of ATF3 −/− mice fed a HFD for 12 weeks with or without ATF3 inducer, ST32da, at 2 mg kg-1 per day. a Body weight. b Food intake.
c Glucose tolerance test (GTT). d Insulin tolerance test (ITT). e Change in adipose tissue depot weight in BAT and WAT. f mRNA level of ChREBP and SCD1 in iWAT.
g Liver weight. h H&E staining of iWAT and BAT; adipocyte size (um 2 ) and number per area (mm 2 ). Scale bar = 100 μm. For a, ATF3 -/-(n = 5), ATF3 -/-+2 mg kg -1 per day ST32da (n = 4). For b, n = 12 per group. For c, d, ATF3 -/-(n = 5), ATF3 -/-+2 mg kg -1 per day ST32da (n = 4). For e, ATF3 -/-(n = 6), ATF3 -/-+2 mg kg -1 per day ST32da (n = 5). For f, n = 5 per group. For g, ATF3 -/-(n = 6), ATF3 -/-+2 mg kg -1 per day ST32da (n = 5). For h, n = 3 per group in H& E staining; n = 4 per group in adipocyte size;
ATF3 -/-(n = 4), ATF3 -/-+2 mg kg -1 per day ST32da (n = 3) in adipocyte number/area (mm 2 ). Data are presented as mean ± SEM.
